The obesity–liver connection: shaping the future of metabolic care
Global momentum around tackling obesity is growing. Obesity is a major driver of liver disease and other health conditions, yet health systems and policy still often treat them in silos.
But now, with a landmark resolution on steatotic liver disease (SLD) on the table at 79th World Health Assembly, is this the moment we unlock the global challenge of obesity?
In this session, experts from government, advocacy and industry will explore how aligning these agendas can unlock real policy progress to transform metabolic health.
Panelists will discuss how to move beyond a narrow focus on weight loss towards truly integrated metabolic care.
Held on the sidelines of the World Health Assembly, our expert panel will cover:
How countries can translate global commitments on SLD and obesity into meaningful policy reform
The significant impact on patients, if integrated poicies reflected the interconnected nature of cardiovascular-renal-metabolic (CRM) conditions
How to ensure early screening and detection sits at the heart of change
Speakers will include:
Larry Holden, CEO and President, Global Liver Institute
Prof. Mohamed Hassany, Assistant Minister of Health for Projects and Public Health Initiatives, Egypt
Dr Pedro Gullón Tosio, Director General of Public Health and Equity in Health, Ministry of Health of Spain
Vani Manja, Corporate SVP, Head of Therapy Area Obesity/Liver Health, Boehringer Ingelheim
This event is organized by Boehringer Ingelheim - please click here to check out all of our events at the 79th World Health Assembly